PowerShares Dynamic Biotech & Genome ETF

Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.

Ionis Pharmaceuticals (IONS), a leading therapeutics company, develops and markets drugs for life-threatening diseases.

BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.

In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

Wall Street analysts expect Amgen’s (AMGN) revenues to decrease marginally by ~0.1% to $5.769 billion during the third quarter.

Today, Biogen (BIIB) reported EPS of $7.40 on revenues of ~$3.44 billion. BIIB beat the EPS estimate of $6.78 on revenues of ~$3.33 billion.

Interferon contributed ~18% of Biogen’s total revenues. Analysts expect the revenues to decrease during the third quarter.

On September 28, Ionis Pharmaceuticals received one “strong buy” rating, three “buy” ratings, seven “hold” ratings, and two “sell” ratings.

Wall Street analysts estimate Ionis Pharmaceuticals (IONS) will report year-over-year growth of ~34.8% in revenues to $612.5 million in 2018 as compared to revenues of $507.7 million during 2017.

Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.

Wall Street analysts estimate that Ionis’s (IONS) Q2 2018 revenues will rise ~30.0% to $135.5 million as compared to $104.2 million in Q2 2017.

Ionis Pharmaceuticals’ (IONS) Spinraza (nusinersen) is a drug designed for the treatment of spinal muscular atrophy.

Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

Gilead’s portfolio As discussed previously, Gilead Sciences’ (GILD) portfolio includes antiviral drugs and other drugs. Whereas its antiviral products include those for hepatitis C, HIV, and hepatitis B infections, its other drugs include oncology, cardiovascular, inflammation, respiratory, and other products. HIV and hepatitis B products The above chart compares revenue for key HIV and hepatitis B products, which include […]

Myriad Genetics (MYGN) announced positive results from its Impact study, which evaluated the effectiveness of the GeneSight precision medicine test.

Harvoni is the top-selling drug in Gilead Sciences’ (GILD) portfolio. The drug is used for the treatment of genotype-1 hepatitis C virus (or HCV) infection.

Ionis Pharmaceuticals (IONS) has been one of the leading pharmaceutical companies in the RNA-targeted therapeutic space for over 26 years.

Biogen (BIIB) stock has risen ~0.40% in 2Q17 and ~4.1% year-to-date as of July 7, 2017.

Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.

In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.

Incyte has classified its oncology product portfolio into targeted anti-cancer therapies and immuno-oncology or immunotherapies.

Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.

While Neurocrine Biosciences (NBIX) invented and developed Elagolix until Phase 2 trials, it is currently being tested in Phase 3 trials by AbbVie (ABBV).

Gilead’s oncology portfolio includes Zydelig, which is used in combination with rituximab for the treatment of chronic lymphocytic leukemia (or CLL).

Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.

After the UK’s decision to withdraw from the EU, a sudden shock hit global markets on June 24. BioMarin lost ~11% of its value in the subsequent two days.

Based on the recommendations of eight brokerage firms, a Bloomberg survey reported that 100% of analysts gave Neurocrine Biosciences “buy” recommendations.

Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. For oncology, its product portfolio includes targeted therapies as well as immunotherapies.

In this series, we’ll look at the performance of Incyte’s existing products and other factors that are driving the company’s revenues and valuation.

Adcetris is an anti-CD30 monoclonal antibody that targets CD30, which is a marker for lymphoma.

Incyte, a Delaware-based biopharmaceutical company, is focused on developing and commercializing oncology products to cater to unmet medical needs.

Vimizim contributed 26% to the top line of BioMarin Pharmaceutical in 2015. Meanwhile, the number of patients on Vimizim rose by 10% during 4Q15 over 3Q15.

PBE’s biotechnology subsector is trading below its 100-day moving average by 3.0%, but above it 20-day and 50-day averages by 1.3% and 4.0%, respectively.

As of November 2015, PJP has outperformed the market, with a YTD return of 6.5%. The fund’s top ten holdings represent 52.41% of its total portfolio.

The PowerShares Dynamic Pharmaceuticals Portfolio ETF (PJP) is a smart beta fund that tracks the performance of the Dynamic Pharmaceutical Intellidex Index.